Rafarma Pharmaceuticals (RAFA) Commences Preparation of Audited Financials
May 12 2014 - 9:15AM
Rafarma Pharmaceuticals, Inc. (Pink Sheets:RAFA) has commenced a
formal audit to provide additional transparency in its public
filings with a forward view to upgrading its public stock listing.
Rafarma has engaged RBSM, LLP, a highly-regarded accounting firm
registered with the Public Company Accounting Oversight Board to
conduct its independent financial audit.
"Rafarma's formal financial audit is another important step in
the Company's advancement in the public markets. It places Rafarma
within a select group of OTC companies and opens the door to a
potential upgraded listing" said David Anderson, CEO.
About Rafarma Pharmaceuticals, Inc.
Operating from a new 270,000 square-foot state-of-the-art
manufacturing and distribution facility in Russia, Rafarma
Pharmaceuticals produces generic antibiotics and specialty
pharmaceuticals in addition to its own line of proprietary products
that are approved by the Ministry of Health of Russian Federation.
For the last three years, the Russian Government has been highly
focused on bolstering the development of the nation's domestic
pharmaceutical industry. Rafarma's mission is to work under the
auspices of these aggressive federal initiatives to fast-track the
modernization of Russia's pharmaceutical industry.
For more information on Rafarma Pharmaceuticals, visit:
http://rafarma.com
Facebook:www.facebook.com/Rafarmainfo; Twitter:
www.twitter.com/Rafarmainfo
For more information on VEBank, visit: http://www.veb.ru/en/
Safe Harbor Statement
Matters discussed in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. When used in this press release, the words
"anticipate," "believe," "estimate," "may," "intend," "expect" and
similar expressions identify such forward-looking statements.
Actual results, performance or achievements could differ materially
from those contemplated, expressed or implied by the
forward-looking statements contained herein. These forward-looking
statements are based largely on the expectations of the Company and
are subject to a number of risks and uncertainties. These include,
but are not limited to: the impact of economic, competitive and
other factors affecting the Company and its operations, markets,
product, and distributor performance.
CONTACT: Dave Anderson, CEO
Phone: 801-210-7135
IR@Rafarma.com
Rafarma Pharmaceuticals (PK) (USOTC:RAFA)
Historical Stock Chart
From Nov 2024 to Dec 2024
Rafarma Pharmaceuticals (PK) (USOTC:RAFA)
Historical Stock Chart
From Dec 2023 to Dec 2024